Haematological malignancies are a diverse group of cancers that affect the blood, bone marrow and lymphatic systems. Laboratory diagnosis of haematological malignancies is dependent on combining several technologies, including morphology, immunophenotyping, cytogenetics... View more
1.National Institute for Health and Care Excellence (2016) Haematological cancers: improving outcomes (NG47). www.nice.org.uk/guidance/ng47
2.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, 2008
3.Swerdlow S et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20):2375
4.Arber D et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20):2391
5.LaCasce A et al. Potential impact of pathologic review on therapy in non-Hodgkin's lymphoma (NHL): Analysis from the national comprehensive cancer network (NCCN) NHL outcomes project. Blood. 2005;106 (11):789A.
6.Lester JF et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. British Journal of Haematology. 2003;123(3):463-8.
7.Proctor IEM,et al. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. Journal of Clinical Oncology. 2011;29(11):1431-5.
8. National Institute for Clinical Excellence (2003) Improving outcomes in haemato-oncology cancer (CSG3) www.nice.org.uk/guidance/csg3
9.Bowen JM et al. Lymphoma diagnosis at an academic centre: Rate of revision and impact on patient care. British Journal Haematology. 2014;166 (2):202-8.
10. Chang C et al. Hematopathologic discrepancies between referral and review diagnoses: A gap between general pathologists and hematopathologists. Leukaemia and Lymphoma. 2014;55 (5):1023-30.